BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Price & Overview
BIT:1BMRN • US09061G1013
Current stock price
The current stock price of 1BMRN.MI is 48.12 EUR. Today 1BMRN.MI is down by -5.09%.
1BMRN.MI Key Statistics
- Market Cap
- 9.244B
- P/E
- 21.58
- Fwd P/E
- 12.35
- EPS (TTM)
- 2.23
- Dividend Yield
- N/A
1BMRN.MI Stock Performance
1BMRN.MI Stock Chart
1BMRN.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BMRN.MI.
1BMRN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI. 1BMRN.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
1BMRN.MI Earnings
On October 27, 2025 1BMRN.MI reported an EPS of -0.16 and a revenue of 776.13M. The company missed EPS expectations (-142.18% surprise) and missed revenue expectations (-2.53% surprise).
1BMRN.MI Forecast & Estimates
32 analysts have analysed 1BMRN.MI and the average price target is 80.11 EUR. This implies a price increase of 66.47% is expected in the next year compared to the current price of 48.12.
For the next year, analysts expect an EPS growth of 28.21% and a revenue growth 12.62% for 1BMRN.MI
1BMRN.MI Groups
Sector & Classification
1BMRN.MI Financial Highlights
Over the last trailing twelve months 1BMRN.MI reported a non-GAAP Earnings per Share(EPS) of 2.23. The EPS increased by 52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| Debt/Equity | 0.1 |
1BMRN.MI Ownership
1BMRN.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 28.77 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1BMRN.MI
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Company Info
IPO: 1999-07-23
BIOMARIN PHARMACEUTICAL INC
770 Lindaro Street
San Rafael California CALIFORNIA US
Employees: 3040
Phone: 14155066700
BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI FAQ
Can you describe the business of BIOMARIN PHARMACEUTICAL INC?
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
What is the current price of 1BMRN stock?
The current stock price of 1BMRN.MI is 48.12 EUR. The price decreased by -5.09% in the last trading session.
Does BIOMARIN PHARMACEUTICAL INC pay dividends?
1BMRN.MI does not pay a dividend.
How is the ChartMill rating for BIOMARIN PHARMACEUTICAL INC?
1BMRN.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of 1BMRN stock?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for 1BMRN stock?
The PE ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 21.58. This is based on the reported non-GAAP earnings per share of 2.23 and the current share price of 48.12 EUR.